2. Search Result
Search Result
Results for "

N-type

" in MedChemExpress (MCE) Product Catalog:

40

Inhibitors & Agonists

11

Peptides

3

Natural
Products

3

Isotope-Labeled Compounds

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P0062B
    Ziconotide acetate
    1 Publications Verification

    SNX-111 acetate

    		 Calcium Channel Cardiovascular Disease Inflammation/Immunology Cancer
    Ziconotide acetate (SNX-111 acetate), a peptide, is a potent and selective block of N-type calcium channels antagonist. Ziconotide acetate reduces synaptic transmission, and can be used for chronic pain research .
    Ziconotide acetate
  • HY-U00236
    PD0176078

    		Calcium Channel Cardiovascular Disease
    PD0176078 is a newly found N-type Calcium channel blocker.
    PD0176078
  • HY-W570888
    2'-O,4'-C-Methylenecytidine

    LNA-C(Bz)

    		 Nucleoside Antimetabolite/Analog Cancer
    2'-O,4'-C-Methylenecytidine (LNA-C(Bz)) is a bicyclic nucleoside analogue with fixed N-type conformation. 2'-O,4'-C-Methylenecytidine can be used to synthesize oligonucleotides. 2'-O,4'-C-Methylenecytidine forms duplexes with complementary DNA and RNA strands .
    2'-O,4'-C-Methylenecytidine
  • HY-121119
    MRS 1523
    4 Publications Verification

    		 Adenosine Receptor Calcium Channel Cardiovascular Disease Neurological Disease Inflammation/Immunology
    MRS 1523 is a potent and selective adenosine A3 receptor antagonist with Ki values of 18.9 nM and 113 nM for human and rat A3 receptors, respectively. In rat this corresponds to selectivities of 140- and 18-fold vs A1 and A2A receptors, respectively. MRS 1523 can exert antihyperalgesic effect through N-type Ca channel block and action potential inhibition in isolated rat dorsal root ganglion (DRG) neurons .
    MRS 1523
  • HY-100310
    N-type calcium channel blocker-1

    		Calcium Channel Neurological Disease
    N-type calcium channel blocker-1 is an orally active compound which shows high affinity to functionally block N-type calcium channels with an IC50 of 0.7 μM in the IMR32 assay.
    N-type calcium channel blocker-1
  • HY-120751
    TROX-1

    		Calcium Channel Neurological Disease
    TROX-1 is an N-type calcium channel (CaV2.2) inhibitor with an IC50 value of 0.11 μM. TROX-1 can be used in chronic pain research .
    TROX-1
  • HY-P0062
    Ziconotide

    SNX-111

    		 Calcium Channel Neurological Disease Inflammation/Immunology Cancer
    Ziconotide (SNX-111), a peptide, is a potent and selective block of N-type calcium channels antagonist. Ziconotide reduces synaptic transmission, and can be used for chronic pain research .
    Ziconotide
  • HY-P1078
    Huwentoxin XVI

    		Calcium Channel Neurological Disease
    Huwentoxin XVI, an analgesic, is a highly reversible and selective mammalian N-type calcium channel (IC50 of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels .
    Huwentoxin XVI
  • HY-P1078A
    Huwentoxin XVI TFA

    		Calcium Channel Neurological Disease
    Huwentoxin XVI TFA, an analgesic, is a highly reversible and selective mammalian N-type calcium channel (IC50 of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI TFA has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels .
    Huwentoxin XVI TFA
  • HY-P0062A
    Ziconotide TFA

    SNX-111 TFA

    		 Calcium Channel Neurological Disease Inflammation/Immunology Cancer
    Ziconotide TFA (SNX-111 TFA), a peptide, is a potent and selective block of N-type calcium channels antagonist. Ziconotide TFA reduces synaptic transmission, and can be used for chronic pain research .
    Ziconotide TFA
  • HY-P5869
    Kurtoxin

    		Calcium Channel Sodium Channel Neurological Disease
    Kurtoxin is a selective Cav3 (T-type) voltage-gated Ca 2+ channel gating inhibitor with a Kd of 15 nM for Cav3.1 (α1G T-type) Ca 2+ channel. Kurtoxin can interact with high affinity with native neuronal high-threshold L-type, N-type, and P-type Ca 2+ channels in central and peripheral neurons. Kurtoxin also shows cross-reactivity with voltage-gated Na + channel .
    Kurtoxin
  • HY-N0601
    Ginsenoside Rf

    Panaxoside Rf

    		 Calcium Channel Endogenous Metabolite Neurological Disease Cancer
    Ginsenoside Rf is a trace component of ginseng root. Ginsenoside Rf inhibits N-type Ca 2+ channel.
    Ginsenoside Rf
  • HY-121119R
    MRS 1523 (Standard)

    		Adenosine Receptor Calcium Channel Cardiovascular Disease Neurological Disease Inflammation/Immunology
    MRS 1523 (Standard) is the analytical standard of MRS 1523. This product is intended for research and analytical applications. MRS 1523 is a potent and selective adenosine A3 receptor antagonist with Ki values of 18.9 nM and 113 nM for human and rat A3 receptors, respectively. In rat this corresponds to selectivities of 140- and 18-fold vs A1 and A2A receptors, respectively. MRS 1523 can exert antihyperalgesic effect through N-type Ca channel block and action potential inhibition in isolated rat dorsal root ganglion (DRG) neurons .
    MRS 1523 (Standard)
  • HY-103318
    PD173212
    2 Publications Verification

    		 Calcium Channel Neurological Disease
    PD173212 is a selective N-type voltage sensitive calcium channel (VSCC) blocker, with an IC50 of 36 nM in IMR-32 assays.
    PD173212
  • HY-147638
    MONIRO-1

    		Calcium Channel Neurological Disease
    MONIRO-1 is a T-type and N-type calcium channel blocker with IC50 values of 34, 3.3, 1.7 and 7.2 µM against hCav2.2, hCav3.1, hCav3.2 and hCav3.3, respectively. MONIRO-1 has low activity against L-type calcium channels. MONIRO-1 can be used for the study of pain and epilepsy .
    MONIRO-1
  • HY-D0949
    Pyronine B

    		Fluorescent Dye Others
    Pyronine B is an organic cationic dye. Pyronin B as a solution-processable and heating-free n-type dopant can be used for soft electronics .
    Pyronine B
  • HY-119373
    Cav 2.2 blocker 1
    1 Publications Verification

    		 Calcium Channel Neurological Disease
    Cav 2.2 blocker 1 (compound 9) is a N-type calcium channel (Cav 2.2) blocker for the treatment of pain, with an IC50 of 1 nM .
    Cav 2.2 blocker 1
  • HY-17404
    Cilnidipine
    2 Publications Verification

    FRC-8653

    		 Calcium Channel Cardiovascular Disease
    Cilnidipine is a long-acting, second-generation dihydropyridine Ca 2+-channel blocker on L and N-type Ca 2+ channel . Antihypertensive effects .
    Cilnidipine
  • HY-131942
    sFTX-3.3

    		Calcium Channel Neurological Disease
    sFTX-3.3 is a Ca 2+ channel antagonist with IC50s of approximately 0.24 mM and 0.70 mM against P-type and N-type channels .
    sFTX-3.3
  • HY-14462
    NP118809

    39-1B4

    		 Calcium Channel Cardiovascular Disease
    NP118809 is a potent N-type calcium channel blocker, with an IC50 of 0.11 μM; also less potently inhibits L-type calcium channel with an IC50 of 12.2 μM.
    NP118809
  • HY-N0601R
    Ginsenoside Rf (Standard)

    Panaxoside Rf (Standard)

    		 Reference Standards Calcium Channel Endogenous Metabolite Neurological Disease Cancer
    Ginsenoside Rf (Standard) is the analytical standard of Ginsenoside Rf. This product is intended for research and analytical applications. Ginsenoside Rf is a trace component of ginseng root. Ginsenoside Rf inhibits N-type Ca2+ channel.
    Ginsenoside Rf (Standard)
  • HY-17404S
    Cilnidipine-d7

    FRC-8653-d7

    		 Isotope-Labeled Compounds Calcium Channel Cardiovascular Disease
    Cilnidipine-d7 is deuterium labeled Cilnidipine. Cilnidipine is a long-acting, second-generation dihydropyridine Ca2+-channel blocker on L and N-type Ca2+ channel . Antihypertensive effects .
    Cilnidipine-d7
  • HY-41076
    Ca2+ channel agonist 1
    1 Publications Verification

    		 Calcium Channel CDK Neurological Disease
    Ca 2+ channel agonist 1 is an agonist of N-type Ca 2+ channel and an inhibitor of Cdk2, with EC50s of 14.23 μM and 3.34 μM, respectively, and is used as a potential treatment for motor nerve terminal dysfunction.
    Ca2+ channel agonist 1
  • HY-17404R
    Cilnidipine (Standard)

    FRC-8653 (Standard)

    		 Reference Standards Calcium Channel Cardiovascular Disease
    Cilnidipine (Standard) is the analytical standard of Cilnidipine. This product is intended for research and analytical applications. Cilnidipine is a long-acting, second-generation dihydropyridine Ca 2+-channel blocker on L and N-type Ca 2+ channel . Antihypertensive effects .
    Cilnidipine (Standard)
  • HY-P5179
    Huwentoxin I

    HWTX-I

    		 Calcium Channel Sodium Channel Neurological Disease
    Huwentoxin I (HWTX-I) is a peptide toxin that inhibits voltage-gated sodium channels and N-type calcium channels. Huwentoxin I inhibits sodium channels in rat hippocampus and cockroach dorsal unpaired median (DUM) neurons with IC50 values of 66.1 and 4.80 nM, respectively .
    Huwentoxin I
  • HY-118974
    PD-151307

    		Calcium Channel Neurological Disease Cancer
    PD-151307 is an N-type calcium channel antagonist with significant inhibitory effects in IMR-32 human neuroblastoma cells, exhibiting an IC50 of 0.32 µM. PD-151307 can be used in research related to cancer therapy, anticonvulsants, and neuropathic pain .
    PD-151307
  • HY-12155
    JNJ-26990990

    		Sodium Channel Calcium Channel Neurological Disease
    JNJ-26990990 is a broad-spectrum antiepileptic agent with oral activity. JNJ-26990990 can inhibit voltage-gated Na + channels and N-type Ca 2+ channels, but has a very weak inhibitory effect on human carbonic anhydrase-II (IC50 = 110 μM) .
    JNJ-26990990
  • HY-17404S1
    Cilnidipine-d4

    FRC-8653-d4

    		 Isotope-Labeled Compounds Calcium Channel Cardiovascular Disease
    Cilnidipine-d4 (FRC-8653-d4) is deuterium labeled Cilnidipine. Cilnidipine is a long-acting, second-generation dihydropyridine Ca 2+-channel blocker on L and N-type Ca 2+ channel . Antihypertensive effects .
    Cilnidipine-d4
  • HY-P2699
    ω-Grammotoxin SIA

    GrTx; ω-GsTx SIA

    		 Calcium Channel Neurological Disease
    ω-Grammotoxin SIA (GrTx) is P/Q and N-type voltage-gated Calcium channels inhibitor. ω-Grammotoxin SIA is also a protein toxin that can be obtained from spider venom. ω-Grammotoxin SIA has the potential to study neurological diseases as well as cardiovascular diseases .
    ω-Grammotoxin SIA
  • HY-12596
    JNJ-26489112

    		Calcium Channel Sodium Channel Potassium Channel Neurological Disease
    JNJ-26489112, a CNS-active agent, exhibits broad-spectrum anticonvulsant activity in rodents against audiogenic, electrically-induced, and chemically-induced seizures. JNJ-26489112 inhibits voltage-gated Na + channels and N-type Ca 2+ channels, and is effective as a K + channel opener. JNJ-26489112 has very weak inhibition of CA-II (IC50=35 μM) and CA-I (18 μM) .
    JNJ-26489112
  • HY-P1079
    ω-Agatoxin TK

    		Calcium Channel Neurological Disease
    ω-Agatoxin TK, a peptidyl toxin of the venom of Agelenopsis aperta, is a potent and selective P/Q type Ca 2+ channel blocker. ω-Agatoxin TK inhibits the high K + depolarisation-induced rise in internal Ca 2+ in cerebral isolated nerve endings with an IC50 of of 60 nM. ω-Agatoxin TK has no effect on L-type, N-type, or T-type calcium channels .
    ω-Agatoxin TK
  • HY-W269511
    NW-1689

    		Drug Derivative Neurological Disease
    NW-1689 is a process-related impurity of safinamide mesilate (SAFM). SAFM is a drug used to treat Parkinson's disease (PD). It is a highly selective and reversible inhibitor of monoamine oxidase-B (MAO-B) and also blocks sodium channels and N-type calcium channels. These effects of SAFM help reduce the breakdown of dopamine and inhibit the release of glutamate. NW-1689 has a similar chemical structure to SAFM and has some similar pharmacological effects as SAFM, and can be used in Parkinson's disease research .
    NW-1689
  • HY-103309A
    ML218 hydrochloride

    		Calcium Channel Neurological Disease
    ML218 hydrochloride is a potent, selective and orally active T-type Ca 2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 hydrochloride inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 hydrochloride has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 hydrochloride can penetrate the blood-brain barrier .
    ML218 hydrochloride
  • HY-103309
    ML218
    2 Publications Verification

    		 Calcium Channel Neurological Disease
    ML218 is a potent, selective and orally active T-type Ca 2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier .
    ML218
  • HY-P1080
    ω-Agatoxin IVA

    		Calcium Channel Neurological Disease
    ω-Agatoxin IVA is a potent, selective P/Q type Ca 2+ (Cav2.1) channel blocker with IC50s of 2 nM and 90 nM for P-type and Q-type Ca 2+ channels, respectively. ω-Agatoxin IVA (IC50, 30-225 nM) inhibits glutamate exocytosis and calcium influx elicited by high potassium. ω-Agatoxin IVA also blocks the high potassium-induced release of serotonin and norepinephrine. ω-Agatoxin IVA has no effect on L-type or N-type calcium channels .
    ω-Agatoxin IVA
  • HY-P1080A
    ω-Agatoxin IVA TFA
    1 Publications Verification

    		 Calcium Channel Neurological Disease
    ω-Agatoxin IVA TFA is a potent, selective P/Q type Ca 2+ (Cav2.1) channel blocker with IC50s of 2 nM and 90 nM for P-type and Q-type Ca 2+ channels, respectively. ω-Agatoxin IVA TFA (IC50, 30-225 nM) inhibits glutamate exocytosis and calcium influx elicited by high potassium. ω-Agatoxin IVA TFA also blocks the high potassium-induced release of serotonin and norepinephrine. ω-Agatoxin IVA TFA has no effect on L-type or N-type calcium channels .
    ω-Agatoxin IVA TFA
  • HY-103309S
    ML218-d9

    		Calcium Channel Neurological Disease
    ML218-d9 is the deuterium labeled ML218. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier .
    ML218-d9
  • HY-134615
    Mead ethanolamide

    		Cannabinoid Receptor Endogenous Metabolite Neurological Disease
    Mead ethanolamide is an endogenous cannabinoid receptor agonist with Kd values of 753 nM and 1810 nM against CB1 and CB2, respectively .
    Mead ethanolamide
  • HY-148503
    5'-ODMT cEt N-Bz A Phosphoramidite (Amidite)

    		Nucleoside Antimetabolite/Analog Others
    5'-ODMT cEt N-Bz A Phosphoramidite (Amidite) is a nucleoside phosphoramidite monomer used to synthesize locked nucleic acid (LNA) analog oligonucleotides. It can be used as a building block of antisense oligonucleotides (ASOs) to target complementary RNA sequences. 5'-ODMT cEt N-Bz A Phosphoramidite (Amidite) locks the furanose ring into an N-type conformation through 2',4'-constrained ethyl (cEt) modification, enhancing hybridization affinity and mismatch discrimination with RNA, while significantly improving the resistance of oligonucleotides to exonuclease digestion. 5'-ODMT cEt N-Bz A Phosphoramidite (Amidite) mediates RNase H-dependent mRNA degradation or inhibits translation by forming a stable hybrid with RNA, thereby achieving gene expression regulation. 5'-ODMT cEt N-Bz A Phosphoramidite (Amidite) is mainly used in the development of antisense drugs, gene function research and oligonucleotide synthesis related to disease treatment .
    5'-ODMT cEt N-Bz A Phosphoramidite (Amidite)
  • HY-147639
    Cav 2.2/3.2 blocker 1

    		Calcium Channel Neurological Disease
    Cav 2.2/3.2 blocker 1 (Compound 9e) is a neuronal calcium channel blocker with IC50 values of 78 μM and 80 μM against Cav2.2 and Cav3.2, respectively. Cav 2.2/3.2 blocker 1 can penetrate the CNS .
    Cav 2.2/3.2 blocker 1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: